2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, LGL, Hodgkin Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4338 Analytical performance of the QIAGEN HemeOnc Next-Generation Sequencing Panel for CALR exon 9 frameshift mutation detection in myeloproliferative neoplasms

Simon Michael Hughes, PhD, Gavin Batman2, George Green, PhD3, Vikas Gupta, PhD4, Betty Lamothe, PhD5, Juergen Lauber, PhD6, Richard Watts, BSc7, Jeff Jackson, PhD8, Erin Crowgey, PhD9
1 QIAGEN Manchester Ltd., Manchester, United Kingdom
2 QIAGEN Manchester Ltd., Manchester, United Kingdom
3 Incyte Corporation, Wilmington, Delaware, United States
4 QIAGEN Aarhus, Aarhus, Denmark
5 Incyte Corporation, Wilmington, Delaware, United States
6 QIAGEN GmbH, Hilden, Germany
7 QIAGEN LLC, Germantown, Maryland, United States
8 Incyte Corporation, Wilmington, Delaware, United States
9 Incyte Corporation, Wilmington, Delaware, United States

Background: CALR exon 9 frameshift mutations represent key driver alterations in the myeloproliferative neoplasms (MPNs) essential thrombocythemia and primary myelofibrosis, typically occurring as heterogeneous insertions and/or deletions (InDel) in DNA. CALR exon 9 frameshifts (mutCALR) result in the generation of a novel C-terminal amino acid sequence that drives oncogenic signaling when in complex with thrombopoietin receptor (TPO-R) at the cell surface. Analytical detection of mutCALR can inform disease prognosis and therapy management; however, detection is challenging due to variable mutation lengths, sequence complexities, and alignment ambiguities within this repetitive genomic region. In this study, a hybrid-capture, unique molecular identifier (UMI)–enabled approach was assessed for its ability to reliably detect structurally complex mutCALR in routine genomic profiling workflows.

Methods: The study used the QIAGEN HemeOnc next-generation sequencing (NGS) Panel, a multimodal DNA/RNA NGS assay designed for molecular profiling of genes associated with myeloid malignancies from whole blood, which is currently in development. The assay includes targeted hybrid capture of CALR exon 9 with UMI-enabled library preparation to enable error suppression and accurate variant detection. The assay features a bioinformatics workflow optimized to improve sensitivity by incorporating InDel-guided local realignment and InDel-aware variant calling. Performance was assessed through a comprehensive evaluation incorporating contrived dilution series, commercially available reference standards, characterized cell line material, and whole-blood specimens from patients with MPNs (n=70) and healthy donors (n=10). Studies assessed sensitivity across variant allele frequencies (VAF) using contrived dilution series, as well as evaluation of specificity, repeatability, and concordance with orthogonal NGS, quantitative polymerase chain reaction (PCR), and digital PCR assays, using structured evaluation criteria and replicate-based assessments to support performance characterization.

Results: Across evaluable sequencing runs, all libraries met predefined quality criteria, with mean on-target rates >80% and mean coverage across CALR exon 9 exceeding 500× following UMI collapsing. All expected canonical mutCALR InDels were detected in reference materials, including Type 1 (52-bp deletion) and Type 2 (5-bp insertion), alongside a broader spectrum of less common mutCALR identified in MPN samples.

Using a contrived dilution series of extracted nucleic acids, the panel demonstrated consistent detection of mutCALR down to 2.0% VAF, indicating robust sensitivity for low-frequency variants. No false-positive mutCALR calls were observed in CALR wild-type or healthy donor samples, supporting assay specificity.

Across 70 MPN specimens, strong positive and negative percent agreement was observed with orthogonal methods, with no evidence of systemic bias between assays. Reproducibility was supported by consistent mutCALR detection and VAF estimation (where applicable) across biological and technical replicates, with concordant results across operators, library preparations, and sequencing runs. The assay demonstrated consistent performance across conditions and mutCALR types represented in the cohort, with Type 1 detected in 13/70 specimens, Type 2 in 10/70 specimens, and 10 additional mutCALR detected, including those with alternative breakpoints and lengths.

Conclusions: The QIAGEN HemeOnc NGS Panel provides a step forward in biomarker detection through combined mutation detection with integrated DNA and RNA profiling from a single blood tube using a unified multimodal workflow, enabling comprehensive assessment of genomic and transcriptomic biomarkers within a single assay from a single patient sample. The assay provides accurate and reproducible detection of mutCALR, including those of various lengths and complexity, supported by sensitive detection at low VAF and concordant results across orthogonal methods and replicate analyses. Based on these findings, the QIAGEN HemeOnc NGS Panel has the potential to fulfill an unmet need for a sensitive, specific, and reproducible companion diagnostic for detection of genetic alterations associated with myeloid malignancies, including mutCALR, in whole blood of patients with MPNs.

Simon Michael Hughes, PhD: QIAGEN Manchester Ltd - Stock (publicly traded); QIAGEN Manchester Ltd - Current Employment